Dr Sophie Janbon Director, Early Chemical Development, Pharmaceutical Sciences, R&D
Dr Sophie Janbon is a French citizen, and has lived in UK since 2004. She came for a PhD in crystallisation science at the School of Chemical Engineering and Analytical Sciences (SCEAS) at the University of Manchester. She started as a Senior Crystallisation Scientist at AstraZeneca in 2007. Her main focus was to develop crystallisation processes for Active Pharmaceutical Ingredients. From 2016 she has been working in the early phase of the portfolio, up to Phase IIb. She was promoted in 2017 to Associate Principal Scientist. She soon after became an Associate Director in 2018 by leading a team of specialists in the field of process engineering, crystallisation and particle science. Her passion is inclusion and diversity and she has been involved in several initiatives which includes the RSC Broadening Horizon. Recently she was promoted to Director.
Dr Samuel Owusu-Ware Associate Principal Scientist, Chemical Development On-Market Technical (CD-OMT) Dr Samuel Owusu-Ware obtained BSc in Pharmaceutical Science from the University of Greenwich (UoG) in 2009 and went on to complete his PhD in Materials Science (UoG). After completing his PhD, he has worked in several industries including the food and cosmetics industry as a Solid-States/Materials Scientist. He started his career at AstraZeneca as a Senior Scientist in 2017, working in On-Market Technical. His focus was providing the physical properties expertise to trouble shoot and optimise drug substance manufacturing processes, across the AZ commercial API portfolio. He was promoted to Associate Principal Scientist in 2020 where he leads characterisation strategies to ensure consistent delivery of desired API physical properties for drug product manufacture. He is an advocate in challenging the status quo and passionate in championing BAME in industry.
Made with FlippingBook Learn more on our blog